Patent Grant
7025998
The present invention relates to new compositions to be orally administered as tablets, capsules or powder for extemporaneous suspension, intended to enhance bone health and general well-being in climacteric and menopausal women.
Postmenopausal osteoporosis due to the ovarian hormone deficiency is the most common cause of bone loss in women. The disorder is prevented by the administration of exogenous estrogen hormones, i.e. by an appropriate Hormone Replacement Therapy (HRT). The synthetic estrogen hormones used for this purpose are potent drugs and, if not properly used, may be associated with side effects, especially by long term administration.
The incidence of fractures ascribable to osteoporosis is lower in Asia than in Western countries. This difference has been attributed to the extensive use of soy-based foods [1] and in particular to some isoflavones that are present in soybeans. In fact, the efficacy of the soy isoflavones (SIs) on the trophism of the bones in post-menopause was demonstrated in several clinical studies [2, 3, 4, 5] and is supported by studies in ovariectomized rats [6].
Soybeans contain mainly two isoflavones, genistin and daidzin. Genistin (MW 432.22) is the β-glucoside of genistein (MW 270.24). Daidzin (MW 416.23) is the β-glucoside of daidzein (MW 254.24). Genistin and daidzin are relatively large molecules; they are very water-soluble and highly polar. These properties hinder their absorption from the gastrointestinal tract and therefore the bioavailability of the estrogen moiety.
To be absorbed and rendered bioavailable, the SIs must be hydrolyzed to aglycons, i.e. separated from the glucoside component [7]. This takes place by the action of special enzymes, the glycosidases. However, the human gastrointestinal tract and that of many mammalians does not secrete glycosidases and therefore the isoflavones cannot be hydrolyzed to become bioavailable. Conversely, some micro-organisms of the intestinal flora and in particular some lactic acid bacteria, produce the glycosidases required for the mentioned hydrolytic process that is necessary for the absorption of the SIs [8, 9]. The presence of glycosidase-producing bacteria in the gastrointestinal tract is therefore the prerequisite for the absorption and the efficacy of the SIs.
The intestinal flora varies greatly between individuals and, even in the same subject, it varies in function of the diet, climate, drug therapies, diseases, etc. Thus, in many subjects, the glycosidase production by the intestinal flora can be scarce or even absent, jeopardizing the absorption of the SIs.
Object of the present invention is to provide a composition for oral administration, particularly as a dietary supplement, for the mitigation, relief, and/or prevention of climacteric and postmenopausal disorders affecting women in pre-, peri- and post-menopause, including dismetabolism of bones that causes bone loss and structural changes with an increases of fracture risk.
The present invention provides a composition for the relief and prevention of climacteric and postmenopausal disorders comprising an effective amount of Soy Isoflavones and viable lactic acid bacteria, the composition being provided in dosage forms for oral administration.
The composition includes soy isoflavones with estrogenic activity and lactic acid bacteria to produce glycosidases in the intestine, aimed to split the ingested isoflavone glucosides into the aglycons that can be absorbed and to insure in all subjects the bioavailability of the administered SIs.
The invention also provides a method for the relief and prevention of climacteric and menopausal disorders, comprising the oral administration of an effective amount of the above mentioned composition to an individual in need thereof.
In principle, any type of lactic acid bacteria is suitable for the composition of the invention. In fact, lactic acid bacteria are probiotics that provide several benefits, because:
For the purposes of the invention, lactic acid bacteria consisting of Lactobacillus sporogenes (Bacillus coagulans), hereinafter abbreviated as Ls, is particularly preferred, because the spores of Ls are stable in normal environmental conditions, do not need storage in refrigerator and remain viable in the gastric and biliary secretions that kill most of the other lactic acid bacteria.
The Ls, in particular, produces by a homofermentative process L-lactic acid, i.e. the isomer that enters in our metabolic pathways and is recommended by the World Health Organization because it does not create a systemic acidosis.
For the production of lactic acid, Ls utilizes the undigested fragments of sugars, subtracting these substrates from other harmful species of the intestinal flora, thus hindering their growth and contributing furthermore to the general well being.
For all these reasons, the lactic acid bacteria and in particular the Ls, are very beneficial probiotic agents that, in addition to enhancing the bioavailability of the SIs, provide several benefits for the general well-being.
A further strengthening of bone health can be achieved adding other beneficial principles for bones and joints. One of this is Horsetail (Equisetum arvense) that supplies organic salts of monosilicic acid, soluble entities of silicon easily absorbed in the gastrointestinal tract and therefore easily bioavailable. Silicon, together with phosphorus, fluoride, magnesium and boron, is involved in the processes of deposition of the crystals of hydroxyapatite on the collagen fibrils, i.e. on the organic structures on which the mineral component of the bones is built up. Horsetail contains also equisetonin, a substance with mild diuretic action, useful for correcting water retention often occurring during menopause and causing swelling of the lower limbs and an increase of body weight. It is as well advisable to supplement calcium (together with Vitamin D to favour its absorption and deposition in bone) because in menopause there is always an increased demand for calcium.
Experimental
The goal of the experimental part was to investigate the role of the different ingredients in the prevention of bone loss in ovariectomized rats, a well-known model of postmenopausal osteoporosis [6].
Briefly, 95 days old Sprague-Dawley rats were ovariectomized under equitesin anaesthesia 3 ml/kg body weight intraperitoneal (equitesin is a mixture of pentobarbital, ethanol, chloral hydrate, propylene glycol, magnesium sulphate dissolved in water). The animals were divided into 4 groups of 8 animals each. A 5th group of 8 animals was sham operated and kept as non-ovariectomized controls. The rats had free access to water and were fed ad libitum with Harlan diet for rodents enriched with calcium carbonate (0.1 g/kg diet) and cholecalciferol (1 μg/kg diet). SIs and Ls were suspended in 0.5% hy-droxy-propyl-methyl-cellulose in water, hereinafter called VEHICLE, and daily administered with gastric tube in a dose of 10 ml/kg body weight.
The groups were treated as follows.
Group 1. Sham operated, non-ovariectomized controls: VEHICLE
Group 2. Ovariectomized conrols: VEHICLE
Group 3. Ovariectomized treated with SIs: genistin 0.5 mg/kg body weight+daidzin 0.5 mg/kg body weight
Group 4. Ovariectoinized treated with SIs+Ls: genistin 0.5 mg/kg body weight+daidzin 0.5 mg/kg body weight+8 million per kg body weight spores of Ls Group 5. Ovariectoimzed treated with SIs+Ls+Equisetum: genistin 0.5 mg/kg body weight+daidzin 0.5 mg/kg body weight+8 million per kg body weight spores of Ls+1.5 mg/kg body weight Horsetail shoots dry extract (standardized in 7% silicon dioxide).
The doses were based on those generally recommended for human use, adapting them to the body weight of the rats used in the study.
Soy isoflavones: the usual daily doses are 20–80 mg, preferably 40–60 mg.
Lactobacillus sporogenes: the usual daily doses are 75–750 million spores, preferably 250–500 million.
Horsetail: the usual daily doses are equivalent to 3–10 mg silicon dioxide.
Calcium: The Recommended Daily Dietary Allowance (RDDA) in adult women is 800 mg. For the purposes of the invention, a daily dose from 100 to 300 mg is preferred, as supplement to the calcium contained in the normal diet.
Vitamin D3: The RDDA in adult women is 5 μg. For the purposes of the compositions of the invention, a daily dose from 3 to 5 μg is preferred.
Six weeks after ovariectomy, the rats were killed by cervical dislocation under ether anesthesia. The uteri were extracted an immediately weighed, the femurs were freed from the soft tissues, their length was measured with a calliper, volume and density were measured by Archimedes' principle, then they were ashed for 24 h at 640° C. Each ash sample was weighed and dissolved in 6 N HCl. Calcium was measured in the resulting solution by atomic absorption spectrophotometry and phosphorus by calorimetric analysis.
The averages and standard errors of the different results were calculated and the significance between values estimated by Student's t-test.
The results obtained at the end of the study are reported in Table 1 and can be summarized as follows.
1. Six weeks after ovariectomy there was no significant change of body weight in any of the ovariectomized animal groups vs. sham operated animals (Group 1).
2. Conversely, in the ovariectomized controls (Group 2) there was a very significant decrease of the weight of uterus and a significant decrease in the length, density, ash weight, calcium and phosphorus content of the femurs, showing the negative effects of the estrogen deficiency on bone trophism.
3. The administration of SIs (Group 3) had no significant effects (vs. Group 2) on body weight and on uterus (absence of stimulation of alpha estrogen receptors), but increased significantly the femoral length and the bone phosphorus, showing a moderate positive effect on bone trophism.
4. The addition of Ls to SIs (Group 4) notably and surprisingly improved bone trophism, as shown by the significant increase of all bone trophism markers (femur length, density, ash weight, calcium and phosphorus content), supporting the rationale of the SIs−Ls combination to enhance the positive effects of the SIs on bone by favouring the bioavailability of the SIs.
5. The further addition of Horsetail extract (Group 5) elicited a further unexpected improvement in all bone trophism markers (femur length, density, ash weight, calcium and phosphorus content), confirming the anabolic effects of this natural herbal product on the bone.
In conclusion, Ls remarkably strengthens the anabolic effects of SIs on the bone, due to the enhancement of the bioavailability of SIs and to the enhancement of intestinal calcium and phosphorus absorption elicited by the probiotic properties of Ls. The addition of Horsetail extract promotes a further beneficial effect on bone anabolism. Notably, neither SIs nor SIs+Ls, had significant effects on the weight of uterus, showing the absence of the stimulation of the alpha estrogen receptors. This is an important contrast with the effects elicited by estrogen hormones, which enhance bone trophism but may cause in some patients unwanted effects, especially by prolonged use, due to the stimulation of the alpha estrogen receptors by these agents.
The study supports therefore the rationale of the SIs+Ls combination as a natural and well tolerated treatment to prevent bone loss due to the deficiency of estrogen hormones caused by ovariectomy in the rat, which occurs also in women after menopause. The addition of Horsetail extract reinforces the prevention of bone loss elicited by the SIs+Ls combination.
Table 1. Results Found in the Different Groups after 6 Weeks of Treatment. Averages and Standard Errors
N of body weight and uterus=8; N of femur data=16. Percent changes vs. ovariectomized controls of Group 2 are also reported. The significant changes (Pt<0.05) are in italics.
aPt NS vs. Group 1
bPt NS vs. Group 2
cPt < 0.001 vs. Group 1
dPt < 0.05 vs. Group 1
ePt < 0.001 vs. Group 2
fPt = 0.05 Group 2
gPt < 0.05 vs. Group 2
The following are examples that describe possible practical application of the present invention but do not limit the invention to the examples.
The following formulation regards the active ingredients and the excipients (with their technical functions) that can be used to formulate tablets for oral administration under the present invention.
The daily dose is contained in a single tablet. The tablets are prepared according to the current technical knowledge and without the need of any particular or special procedure. In summary the following production steps are requested:
The needed ingredients are listed in the following Tables.
Lactobacillus sporogenes 15 billion/g
The following formulation regards the active ingredients and the excipients (with their technical functions) that can be used to prepare capsules for oral administration under the present invention.
The daily dose is carried in two capsules. The capsules are prepared according to the current technical knowledge and without the need of any particular or special procedure. In summary the following production steps are requested:
The needed ingredients are listed in the following Tables.
Equisetum arvense 7% dry extract
Lactobacillus sporogenes 15 billion/g
The following formulation regards the active ingredients and the excipients (with their technical functions) that can be used to formulate a powder suitable to prepare an oral suspension.
The daily dose is carried in a single portion of powder. The portions are contained in sachets consisting of an external paper layer, an aluminium interface and an internal polyethylene layer. The sachets are prepared according to the current technical knowledge and without the need of any particular or special procedure. In summary the following production steps are requested:
The needed ingredients are listed in the following Tables.
Equisetum arvense 7% dry extract
Lactobacillus sporogenes 15 billion/g
| Number | Name | Date | Kind |
|---|---|---|---|
| 4110477 | Naruse et al. | Aug 1978 | A |
| 4220660 | Brock | Sep 1980 | A |
| 5498631 | Gorbach et al. | Mar 1996 | A |
| 5516528 | Hughes et al. | May 1996 | A |
| 5702752 | Gugger et al. | Dec 1997 | A |
| 5792503 | Gugger et al. | Aug 1998 | A |
| 5830887 | Kelly | Nov 1998 | A |
| 6033714 | Gugger et al. | Mar 2000 | A |
| 6150399 | Patel et al. | Nov 2000 | A |
| 6171638 | Gugger et al. | Jan 2001 | B1 |
| 6261565 | Empie et al. | Jul 2001 | B1 |
| 6294166 | Hsia | Sep 2001 | B1 |
| 6344217 | Ruepp | Feb 2002 | B1 |
| 6375994 | Paul et al. | Apr 2002 | B1 |
| 6391309 | Empie et al. | May 2002 | B1 |
| 6447809 | Krumhar et al. | Sep 2002 | B1 |
| 6497906 | Kelly | Dec 2002 | B1 |
| 6716424 | Shimizu et al. | Apr 2004 | B1 |
| 20020114786 | Fabre et al. | Aug 2002 | A1 |
| 20020182274 | Lu | Dec 2002 | A1 |
| 20030008023 | Lu | Jan 2003 | A1 |
| 20030031726 | Hendricks | Feb 2003 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 002 495 | Feb 1984 | EP |
| 1025850 | Aug 2000 | EP |
| 1 186 295 | Mar 2002 | EP |
| 1186295 | Mar 2002 | EP |
| 09238647 | Sep 1997 | JP |
| 2001 333692 | Dec 2001 | JP |
| 2001333692 | Dec 2001 | JP |
| 2001340059 | Dec 2001 | JP |
| Number | Date | Country | |
|---|---|---|---|
| 20040241260 A1 | Dec 2004 | US |
